ArticleBrain and behavior2018
Evaluation of Memorial Sloan-Kettering Cancer Center and International Extranodal Lymphoma Study Group prognostic scoring systems to predict Overall Survival in intracranial Primary CNS lymphoma.
Article in Brain and behavior, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 42 citations in OpenAlex.
- Immunohistochemistry for c-myc and bcl-2 overexpression improves risk stratification in primary central nervous system lymphoma.Hematological oncology · 2020Trial
- The Endothelial Activation and Stress Index (EASIX) at diagnosis is associated with survival in primary central nervous system lymphoma.British journal of haematology · 2026Observational
- A Prognostic Model Incorporating Age and Systemic Inflammation Response Index for Primary CNS Lymphoma.Current oncology (Toronto, Ont.) · 2026Article
- Length of hospital stay and outcome in primary central nervous system lymphoma: a French retrospective multicentric study.Annals of hematology · 2025Article
- Comparison of outcomes in postinduction strategies for primary central nervous system lymphoma: a Mayo Clinic experience.Blood advances · 2025Article
- Impact of Systemic and Radiation Therapy on Survival of Primary Central Nervous System Lymphoma.Cancers · 2025Article
- Primary Central Nervous System Lymphomas: A Single-Center Experience.Sisli Etfal Hastanesi tip bulteni · 2025Article
- A Nomogram for Predicting Overall Survival in Primary Central Nervous System Lymphoma: A Retrospective Study.Journal of inflammation research · 2025Article
- Clinicopathological risk factors for prognosis and therapeutic response of primary central nervous system lymphoma in China: a single-center retrospective analysis of 118 cases.Annals of hematology · 2025Article
- Surgical Considerations in Treating Central Nervous System Lymphomas: A Case Series of 11 Patients.Current oncology (Toronto, Ont.) · 2024Article
- Pre-treatment systemic inflammation response index and systemic immune inflammation in patients with primary central nerve system lymphoma as a useful prognostic indicator.Journal of neuro-oncology · 2024Article
- Impact of MYC and BCL2 double expression on outcomes in primary CNS lymphoma: a UK multicenter analysis.Blood advances · 2024Article
- Prognostic value of POD18 combined with improved IELSG in primary central nervous system lymphoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Article
- Different patterns of failure in two treatment regimens for primary central nervous system lymphoma, a retrospective analysis of 124 cases in Taiwan.Clinical and experimental medicine · 2023Article
- Article
- Extranodal lymphoma: pathogenesis, diagnosis and treatment.Molecular biomedicine · 2023Review
- Article
- A novel inflammation-related prognostic model for predicting the overall survival of primary central nervous system lymphoma: A real-world data analysis.Frontiers in oncology · 2023Article
- Cranial Radiation Therapy as Salvage in the Treatment of Relapsed Primary CNS Lymphoma.Current oncology (Toronto, Ont.) · 2022Article
- Prognostic significance of pretreatment red blood cell distribution width in primary diffuse large B-cell lymphoma of the central nervous system for 3P medical approaches in multiple cohorts.The EPMA journal · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To evaluate the validity of Memorial Sloan-Kettering Cancer Center (MSKCC) and International Extranodal Lymphoma Study Group (IELSG) prognostic scoring systems for Overall Survival (OS) in intracranial Primary CNS lymphoma (PCNSL) of all patients diagnosed at a single center. Material and Methods: Pretreatment clinical factors including tumor characteristics and histology, treatment, and survival of PCNSL patients with diagnostic biopsies over a 12-year period (2003-2014) were retrieved from a prospective database at Oslo University Hospital. Results: Seventy-nine patients with intracranial PCNSL were identified. The female:male ratio was 1:1.63 and the median age was 65.3 years [range 18.9-80.7]. Involvement of deep brain structures was shown in 63 patients. Six patients were MSKCC risk group 1, 35 patients were in risk group 2, and 38 patients were in risk group 3. International Extranodal Lymphoma Study Group scores were <2 in 17 patients (22%). After a median follow-up of 70.5 months, 55 patients were dead. Median OS was 16.4 months [range 0.2-157.7]. Age, sLDH by recursive partitioning analysis (RPA), Eastern Cooperative Oncology Group score (ECOG), lesion size, involvement of deep brain structures, IELSG score, and MSKCC score were significant factors for OS in univariate analysis. Multivariate analysis confirmed the significance of age ( Conclusions: Our study failed to verify the IELSG, but validated the use of MSKCC for prognostication of OS in intracranial PCNSL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.